Breast CancerPhase 2NCT01556243
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
A Phase 2 study testing therapeutic conventional surgery and whole breast irradiation in people with Breast Cancer, run by Alliance for Clinical Trials in Oncology at 350 sites in United States.
Trial summary
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. Read more about this study
- Who is it for?
- Ages 40 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- therapeutic conventional surgery and whole breast irradiation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 270 participants
- Where
- 350 sitesUnited States
- Study dates
- Jul 2012to 15 Apr 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Registration Inclusion Criteria:
- Age ≥ 40 years per National Comprehensive Cancer Network (NCCN) recommendations for breast conservation.
- Life Expectancy of at least 5 years, excluding diagnosis of breast cancer (Comorbid conditions should be taken into consideration, but breast cancer diagnosis is not a consideration)
- Female Gender - Men are excluded from this study. Male breast cancer is a rare event. Men are rarely candidates for breast conservation surgery due to small breast size. Men are less likely to be candidates for breast conservation surgery if found to have MIBC. Men are rarely candidates for breast conservation surgery due to small breast size. Men are less likely to be candidates for breast conservation surgery if found to have MIBC.
- Foci of Breast Cancer 4.1 Upon clinical exam and pre-operative imaging by mammogram +/- MRI, two or three foci of biopsy proven breast cancer separated by > 2 cm of normal breast tissue. 4.2 Foci must include at least one focus of invasive breast carcinoma with another focus of either invasive breast carcinoma or ductal carcinoma in situ (DCIS). No more than 2 quadrants with biopsy proven breast cancer. 4.3 Note: The shortest distance between lesions must be reported on mammogram +/- MRI and eligibility criteria must be met on both, if both are obtained. 4.4 Note: Patient is eligible for study if lesion is not visualized on all imaging modalities (i.e., any of the lesion(s) is/are visualized on MRI but not on mammogram OR visualized on mammogram but not on MRI). 4.5 Ultrasound cannot be used to determine patient eligibility; eligibility to be determined by bilateral mammogram +/- MRI only. 4.6 Fine needle aspirate of the second or third lesion to document malignancy is allowed if the first focus is shown to be invasive by core needle biopsy. 4.7 Patient may remain on study if, upon pathological assessment, two or three lesions identified on pre-operative imaging represent one contiguous lesion.
- Patients may be registered AFTER surgery and PRIOR TO radiation therapy if either of the criteria is met: 5.1 An area of atypia > 2cm from the index lesion excised at the time of cancer operation is upgraded to DCIS or invasive carcinoma thereby identifying MIBC. OR 5.2 Patient underwent resection of two or three foci of malignancy by breast conservation surgery with a minimum of one invasive focus of breast cancer and a minimum of 2 cm of normal breast tissue between the lesions on final pathology.
- Mammogram Imaging - Bilateral mammogram ≤ 90 days prior to date of surgery. 6.1 Note: For patients undergoing more than 1 breast operation, this is the date of the first breast surgery for breast cancer treatment.
- Staging of Cancer - cN0 or cN1 disease
- ECOG Performance Status (PS) - 0, 1, or 2.
- Ability to Complete Questionnaires - Ability to complete questionnaire(s) by themselves or with assistance
- Ability to Provide Written Informed Consent
- Willing to Return to Enrolling Institution - Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study. Patients are encouraged to return to the enrolling institution; however, patients may receive radiation therapy at a different institution other than the enrolling institution.
Registration Exclusion Criteria:
- Pregnancy, Nursing and Requirement for Contraception - Pregnant women, nursing women and women of childbearing potential who are unwilling to employ adequate contraception (as determined by the treating physician) are excluded from participation. This study involves radiation therapy (WBI) that has known genotoxic, mutagenic and teratogenic effects.
- Size of Single Focus of Disease on Preoperative Imaging - Largest single focus of disease > 5 centimeters by either mammogram or MRI or both. Note: Measurement of the largest single focus should include any satellite lesions within 1 centimeter of the index lesion.
- Prior Staging Procedure - Surgical axillary staging procedure prior to first definitive breast operation. Note: FNA or core needle biopsy of axillary node is permitted.
- Evidence of Metastatic Disease - Clinical or radiographic evidence of metastatic disease
- Prior History of Breast Cancer - Prior history of ipsilateral breast cancer [DCIS, LCIS (lobular cancer in situ) or invasive]
- Staging of Cancer - cNX, cN2, or cN3 disease
- Breast Implants - Breast implants at time of diagnosis. Note: Patients who have had implants previously removed prior to diagnosis are eligible.
- Systemic Illnesses or Concurrent Disease - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would interfere significantly with whole breast irradiation (such as connective tissue disorders, lupus, scleroderma).
- Uncontrolled Intercurrent Illness - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Bilateral Breast Cancer - Prior or current LCIS, DCIS or invasive breast cancer in the opposite breast (i.e., bilateral disease is not allowed).
- Disallowed Prior Treatments - Treatment including radiation therapy, chemotherapy, biotherapy, hormonal therapy for this cancer prior to surgery (i.e., any neoadjuvant chemotherapy or endocrine therapy is not allowed). Patients who undergo surgical resection with breast conservation and then are treated with adjuvant systemic therapy are eligible to enroll prior to the start of radiotherapy.
- Partial Breast Radiation - Planned partial breast radiation.
- Known BRCA Mutations - Patients with known BRCA mutations. Patients who are not tested or whose testing result is not returned at the time of registration are not excluded from registering to this study.
- Other Active Malignancies - Other active malignancy ≤ 5 years prior to registration.
14.1 Exceptions: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.
14.2 Note: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer.
Trial locations and contacts
350 sites in 1 country.
300 sites in 1 country
United States300 sites
Oncare Hawaii, Incorporated-Pali Momi
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Leeward
‘Ewa Beach, Hawaii, 96706
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Lovelace Women's Hospital
Albuquerque, New Mexico, 87109
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Texas Tech University Health Sciences Center-Amarillo
Amarillo, Texas, 79106
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, 50010
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Randolph Hospital
Asheboro, North Carolina, 27203
University of Colorado Cancer Center-Anschutz Cancer Pavilion
Aurora, Colorado, 80045
IU Health West Hospital
Avon, Indiana, 46123
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Saint Agnes Hospital
Baltimore, Maryland, 21229
Eastern Maine Medical Center
Bangor, Maine, 04401
Flaget Memorial Hospital
Bardstown, Kentucky, 40004
Memorial Sloan Kettering Cancer Center-Basking Ridge
Basking Ridge, New Jersey, 07920
Bronson Battle Creek
Battle Creek, Michigan, 49017
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Central Vermont Medical Center
Berlin Corners, Vermont, 05602
Lehigh Valley Hospital-Muhlenberg
Bethlehem, Pennsylvania, 18017
Montana Cancer Consortium NCORP
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Billings Clinic Cancer Center
Billings, Montana, 59107
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
McFarland Clinic PC-Boone
Boone, Iowa, 50036
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Harrison Medical Center
Bremerton, Washington, 98310
Eastern Maine Medical Center Cancer Care
Brewer, Maine, 04412
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Highline Medical Center-Main Campus
Burien, Washington, 98166
University of Vermont College of Medicine
Burlington, Vermont, 05405
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Illinois CancerCare-Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Giradeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
IU Health North Hospital
Carmel, Indiana, 46032
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Centralia Oncology Clinic
Centralia, Illinois, 62801
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Levine Cancer Institute-Tryon
Charlotte, North Carolina, 28203
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Carolina Surgical Clinic of Charlotte PA
Charlotte, North Carolina, 28207
Oncology Specialists of Charlotte
Charlotte, North Carolina, 28207
Carolinas Medical Center/Levine Cancer Institute-Pineville
Charlotte, North Carolina, 28210
Carolinas Medical Center/Levine Cancer Institute-University
Charlotte, North Carolina, 28262
Southern Oncology Specialists-Charlotte
Charlotte, North Carolina, 28262
Levine Cancer Institute-Ballantyne
Charlotte, North Carolina, 28277
Memorial Hospital
Chattanooga, Tennessee, 37404
University of Illinois
Chicago, Illinois, 60612
Adena Regional Medical Center
Chillicothe, Ohio, 54601
The Christ Hospital
Cincinnati, Ohio, 45219
Good Samaritan Hospital-Cincinnati
Cincinnati, Ohio, 45220
Bethesda North Hospital
Cincinnati, Ohio, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, 45255
University of Cincinnati
Cincinnati, Ohio, 45267
Morton Plant Hospital
Clearwater, Florida, 33756
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Big Horn Basin Cancer Center
Cody, Wyoming, 82414
Billings Clinic-Cody
Cody, Wyoming, 82414
Mount Carmel East Hospital
Columbus, Ohio, 43213
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Riverside Methodist Hospital
Columbus, Ohio, 43214
Columbus NCI Community Oncology Research Program
Columbus, Ohio, 43215
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Doctors Hospital
Columbus, Ohio, 43228
Memorial Sloan Kettering Cancer Center-Commack
Commack, New York, 11725
Mercy Hospital
Coon Rapids, Minnesota, 55433
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, 40701
Kootenai Medical Center
Couer D'Alene, Idaho, 83814
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Greater Regional Medical Center
Creston, Iowa, 50801
Parkland Memorial Hospital
Dallas, Texas, 75235
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Oakwood Hospital and Medical Center
Dearborn, Michigan, 48124
Cancer Care Specialists of Central Illinois
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Delaware Radiation Oncology
Delaware, Ohio, 43015
Grady Memorial Hospital
Delaware, Ohio, 43015
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center-Des Moines
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Epic Care-Dublin
Dublin, California, 94568
Memorial Sloan Kettering Cancer Center-West Harrison
East White Plains, New York, 10604
Saint Elizabeth Medical Center South
Edgewood, Kentucky, 41017
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Bay Area Breast Surgeons, Incorporated
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Catholic Health Initiatives NCORP
Englewood, Colorado, 80112
Saint Elizabeth Hospital
Enumclaw, Washington, 98022
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Saint Francis Hospital
Federal Way, Washington, 98003
IU Health Central Indiana Cancer Centers-Fishers
Fishers, Indiana, 46037
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa, 50501
Saint Elizabeth-Fort Thomas
Fort Thomas, Kentucky, 41075
Mary Washington Hospital
Fredericksburg, Virginia, 22401
Unity Hospital
Fridley, Minnesota, 55432
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
CaroMont Breast Surgical Specialists-Gastonia
Gastonia, North Carolina, 28054
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
CHI Health Saint Francis
Grand Island, Nebraska, 68803
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare-Sletten Cancer Institute
Great Falls, Montana, 59405
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301
Saint Vincent Hospital
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311-6519
Cone Health Cancer Center
Greensboro, North Carolina, 27403
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Saint Peter's Community Hospital
Helena, Montana, 59601
Cancer and Blood Specialists-Henderson
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Henderson
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
21st Century Oncology-Henderson
Henderson, Nevada, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Hilton Head Regional Medical Center
Hilton Head Island, South Carolina, 29926
Pulmonary Medicine Center of Chattanooga-Hixson
Hixson, Tennessee, 37343
Oncare Hawaii Inc-POB II
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Kuakini Medical Center
Honolulu, Hawaii, 96817
OnCare Hawaii, Incorporated-Kuakini
Honolulu, Hawaii, 96817
OnCare Hawaii-Liliha
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, 71913
M. D. Anderson Cancer Center
Houston, Texas, 77030
The Methodist Hospital System
Houston, Texas, 77030
Lake Norman Hematology Oncology Specialists-Huntersville
Huntersville, North Carolina, 28078
Southern Oncology Specialists-Huntersville
Huntersville, North Carolina, 28078
Centerpoint Medical Center LLC
Independence, Missouri, 64057
Indiana University-Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
IU Health Methodist Hospital
Indianapolis, Indiana, 46202
Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana, 46202
Allegiance Health
Jackson, Michigan, 49201
McFarland Clinic PC-Jefferson
Jefferson, Iowa, 50129
Capital Region Medical Center-Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Borgess Medical Center
Kalamazoo, Michigan, 49001
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Heartland Hematology and Oncology Associates Incorporated
Kansas City, Missouri, 64118
Research Medical Center
Kansas City, Missouri, 64132
Heartland Hematology and Oncology
Kearney, Nebraska, 68845
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Saint Clare Hospital
Lakewood, Washington, 98499
Fairfield Medical Center
Lancaster, Ohio, 43130
Sparrow Hospital
Lansing, Michigan, 48912
Doctor's Hospital of Laredo
Laredo, Texas, 78045
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89106
Nevada Cancer Research Foundation NCORP
Las Vegas, Nevada, 89106
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
21st Century Oncology-Fort Apache
Las Vegas, Nevada, 89109
21st Century Oncology
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, 89121
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, 89128
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada-Northwest
Las Vegas, Nevada, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Cancer and Blood Specialists-Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, 89149
Comprehensive Cancer Centers of Nevada-Central Valley
Las Vegas, Nevada, 89169
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Saint Luke's East-Lee's Summit
Lee's Summit, Missouri, 64086
Beebe Medical Center
Lewes, Delaware, 19958
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, 40504
Saint Joseph Hospital East
Lexington, Kentucky, 40509
Liberty Radiation Oncology Center
Liberty, Missouri, 64068
Wilcox Memorial Hospital and Kauai Medical Clinic
Lihue, Hawaii, 96766
Saint Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Cedars Sinai Medical Center
Los Angeles, California, 90048
Cedars-Sinai Medical Center
Los Angeles, California, 90048
Jewish Hospital
Louisville, Kentucky, 40202
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
Saints Mary and Elizabeth Hospital
Louisville, Kentucky, 40215
Jewish Hospital Medical Center Northeast
Louisville, Kentucky, 40245
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
North Shore University Hospital
Manhasset, New York, 11030
OhioHealth MedCentral Hospital
Mansfield, Ohio, 44903
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital-Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
OhioHealth Marion General Hospital
Marion, Ohio, 43302
McFarland Clinic PC-Marshalltown
Marshalltown, Iowa, 50158
Contra Costa Regional Medical Center
Martinez, California, 94553
Matthews Radiation Oncology Center
Matthews, North Carolina, 28105
Novant Health Cancer Specialists-Matthews
Matthews, North Carolina, 28105
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53233
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Memorial Regional Cancer Center-Day Road
Mishawaka, Indiana, 46544
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Community Medical Hospital
Missoula, Montana, 59801
Saint Patrick Hospital-Community Hospital
Missoula, Montana, 59802
Carolinas HealthCare System Union
Monroe, North Carolina, 28112
Lake Norman Hematology Oncology Specialists-Mooresville
Mooresville, North Carolina, 28117
Knox Community Hospital
Mount Vernon, Ohio, 43050
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Saint Peter's University Hospital
New Brunswick, New Jersey, 08901
North Shore-LIJ Health System/Center for Advanced Medicine
New Hyde Park, New York, 11040
Westfields Hospital/Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Christiana Gynecologic Oncology LLC
Newark, Delaware, 19713
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, 19713
Helen F. Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Regional Hematology and Oncology PA
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Licking Memorial Hospital
Newark, Ohio, 43055
Newark Radiation Oncology
Newark, Ohio, 43055
Alta Bates Summit Medical Center-Summit Campus
Oakland, California, 94609
Bay Area Tumor Institute
Oakland, California, 94609
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
Alegent Health Immanuel Medical Center
Omaha, Nebraska, 68122
Hematology and Oncology Consultants PC
Omaha, Nebraska, 68122
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Alegent Health Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131
Memorial GYN Plus
Ooltewah, Tennessee, 37363
Vince Lombardi Cancer Clinic-Oshkosh
Oshkosh, Wisconsin, 54904
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Radiation Oncology of Northern Illinois
Ottawa, Illinois, 61350
Menorah Medical Center
Overland Park, Kansas, 66209
Saint Luke's South Hospital
Overland Park, Kansas, 66213
Stanford Cancer Institute
Palo Alto, California, 94304
Midlands Community Hospital
Papillion, Nebraska, 68046
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Illinois CancerCare-Pekin
Pekin, Illinois, 61603
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare-Peru
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Oregon Health and Science University
Portland, Oregon, 97239
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Kootenai Cancer Center
Post Falls, Idaho, 83854
Vassar Brothers Medical Center
Poughkeepsie, New York, 12601
Harrison HealthPartners Hematology and Oncology-Poulsbo
Poulsbo, Washington, 98370
Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas, 66208
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Roger Williams Medical Center
Providence, Rhode Island, 02908
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Annie Penn Memorial Hospital
Reidsville, North Carolina, 27320
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
University of Rochester
Rochester, New York, 14642
Levine Cancer Institute-Rock Hill
Rock Hill, South Carolina, 29732
Memorial Sloan Kettering Cancer Center-Rockville Centre
Rockville Centre, New York, 11570
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Saint Mary's of Michigan
Saginaw, Michigan, 48601
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
About this study
Official title: Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer
Read the detailed description
OBJECTIVES:
Primary
- To assess the local recurrence (LR) rate with breast-conservation in patients with multiple ipsilateral primary breast cancer (MIBC).
Secondary
- To examine the conversion rate to mastectomy secondary to persistent positive margins; poor cosmesis within the first year of attempting breast-conservation surgery (BCS) or inability to satisfy the radiation dose constraints on the boost to the lumpectomy bed of each site of disease.
- To assess whether patients who did not undergo re-excision for close margins (< 2 mm) have a higher local recurrence (LR) rate than patients for whom negative margins were achieved.
- To assess patient's perception of cosmesis and incidence of breast lymphedema.
- To assess incidence of breast lymphedema
- To examine the type and severity of adverse effects of breast conserving surgery and radiation for women with multiple ipsilateral primary breast cancer (MIBC).
- To examine the radiation-related side effects of whole-breast radiation with a boost to 1 large or > 1 lumpectomy site.
OUTLINE: This is a multicenter study.
Patients undergo breast-conserving surgery (BCS) with all lesions resected to negative margins using 1 lumpectomy or 2-3 separate lumpectomy incisions at the discretion of the surgeon. Patients receive adjuvant chemotherapy and/or endocrine therapy at the discretion of the treating medical oncologist based on tumor characteristics.
- Conditions
- Breast Cancer
- Being tested
- therapeutic conventional surgery, whole breast irradiation
- Keywords
- stage IA breast cancer, stage IB breast cancer, stage II breast cancer, ductal breast carcinoma in situ, lobular breast carcinoma in situ
- Medical subject headings
- Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Breast Carcinoma In Situ
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
therapeutic conventional surgeryProcedure or surgery
whole breast irradiationRadiation
| Study group | Role | What they receive |
|---|---|---|
| Breast conservation surgery and radiation therapy | Experimental | Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy. Receives: Procedure: therapeutic conventional surgery; Radiation: whole breast irradiation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Local Recurrence
Local recurrence(LR) defined as histologic evidence of ductal carcinoma in situ or invasive breast cancer in the ipsilateral breast or chest wall assessed up to 5 years. The estimated 5-year cumulative incidence of LR will be reported as a percentage of patients expected to experience a LR at 5 years.
Measured: 5 years
Secondary outcomes (4)
Conversion Rate to Mastectomy
The conversion rate to mastectomy secondary to persistent positive margins; poor cosmesis within the first year of attempting BCS; or inability to satisfy the radiation dose constraints on the boost to the lumpectomy bed of each site of disease.
Measured: 5 years
Severity of Adverse Effects
Severity of adverse effects of breast-conserving surgery and radiation as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be reported as the percentage of patients that experienced a grade 3 or higher adverse event.
Measured: 17 monhts
Radiation-related Side Effects
Radiation-related side effects of whole-breast radiation with a boost to 1 large or > 1 lumpectomy site as assessed by NCI CTCAE version 4.0.
Measured: 17 months
Patient's Perception of Cosmesis
Patient's perception of cosmesis will be assessed at their initial post-operative visit as well as 24 months following completion of WBI using the BREAST-Q subscales: satisfaction with breasts, satisfaction with overall outcome, and physical well-being. Patients registered after surgery will not partake in the pre-operative assessment but will be asked to complete subsequent cosmesis surveys. The total score for each of these subscales will be determined using the BREAST-Q scoring module (http://www.mskcc.org/mskcc/shared/Breast-Q/scoreBQ.html). The BREAST-Q has multiple domains, and each domain score is obtained by transforming the raw scale item responses with the Q-Score software program. Each domain results in an independent score from 0 to 100 (higher scores indicate greater satisfaction or quality of life).
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2012 (estimated)
- Study startJul 2012
- Primary completion1 Jun 2022
- Study completion15 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 270 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Judy Boughey, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01556243
- Sponsor's protocol ID
- ACOSOG-Z11102
- Other IDs
- ACOSOG-Z11102, CDR0000728605, NCI-2012-00707
- Status last verified
- May 2026
- First submitted
- 15 Mar 2012
- Last updated
- 12 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HT, Giuliano AE, Van Zee KJ, Hunt KK, Hahn OM, Carey LA, Partridge AH. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). J Clin Oncol. 2023 Jun 10;41(17):3184-3193. doi: 10.1200/JCO.22.02553. Epub 2023 Mar 28.
PubMed 36977292Cuttino LW, McCall L, Kubicky C, Ballman KV, Le-Petross H, Hunt KK, Haffty B, Rosenkranz KM, Boughey JC. The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Int J Radiat Oncol Biol Phys. 2022 Mar 1;112(3):636-642. doi: 10.1016/j.ijrobp.2021.09.054. Epub 2021 Oct 8.
PubMed 34634438Rosenkranz KM, Ballman K, McCall L, McCarthy C, Kubicky CD, Cuttino L, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC. Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study. Ann Surg Oncol. 2020 Nov;27(12):4650-4661. doi: 10.1245/s10434-020-08893-w. Epub 2020 Jul 22.
PubMed 32699926Rosenkranz KM, Ballman K, McCall L, Kubicky C, Cuttino L, Le-Petross H, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC. The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Ann Surg Oncol. 2018 Oct;25(10):2858-2866. doi: 10.1245/s10434-018-6583-6. Epub 2018 Jul 9.
PubMed 29987605
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
- ClinicalTrials.gov ID
- NCT01556243
- Acronym / sponsor ID
- ACOSOG-Z11102
- Conditions
- Breast Cancer
- Keywords
- stage IA breast cancer, stage IB breast cancer, stage II breast cancer, ductal breast carcinoma in situ, lobular breast carcinoma in situ
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 270 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Jul 2012
- Primary completion
- 1 Jun 2022 (actual)
- Study completion
- 15 Apr 2023 (actual)
- First posted
- 16 Mar 2012 (estimated)
- Results
- Posted 30 Nov 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer
Detailed description
OBJECTIVES:
Primary
- To assess the local recurrence (LR) rate with breast-conservation in patients with multiple ipsilateral primary breast cancer (MIBC).
Secondary
- To examine the conversion rate to mastectomy secondary to persistent positive margins; poor cosmesis within the first year of attempting breast-conservation surgery (BCS) or inability to satisfy the radiation dose constraints on the boost to the lumpectomy bed of each site of disease.
- To assess whether patients who did not undergo re-excision for close margins (< 2 mm) have a higher local recurrence (LR) rate than patients for whom negative margins were achieved.
- To assess patient's perception of cosmesis and incidence of breast lymphedema.
- To assess incidence of breast lymphedema
- To examine the type and severity of adverse effects of breast conserving surgery and radiation for women with multiple ipsilateral primary breast cancer (MIBC).
- To examine the radiation-related side effects of whole-breast radiation with a boost to 1 large or > 1 lumpectomy site.
OUTLINE: This is a multicenter study.
Patients undergo breast-conserving surgery (BCS) with all lesions resected to negative margins using 1 lumpectomy or 2-3 separate lumpectomy incisions at the discretion of the surgeon. Patients receive adjuvant chemotherapy and/or endocrine therapy at the discretion of the treating medical oncologist based on tumor characteristics.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Breast conservation surgery and radiation therapy | Experimental | Procedure: therapeutic conventional surgery, Radiation: whole breast irradiationPatients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy. |
Who may qualify
- Ages
- 40 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| therapeutic conventional surgery | Procedure or surgery | Breast conservation surgery and radiation therapy |
| whole breast irradiation | Radiation | Breast conservation surgery and radiation therapy |
Primary outcome
Local Recurrence
Time frame: 5 years
Local recurrence(LR) defined as histologic evidence of ductal carcinoma in situ or invasive breast cancer in the ipsilateral breast or chest wall assessed up to 5 years. The estimated 5-year cumulative incidence of LR will be reported as a percentage of patients expected to experience a LR at 5 years.
4 secondary outcomes
Conversion Rate to Mastectomy
Time frame: 5 years
Severity of Adverse Effects
Time frame: 17 monhts
Radiation-related Side Effects
Time frame: 17 months
Patient's Perception of Cosmesis
Time frame: 24 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 36977292Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD, Le-Petross HT, Giuliano AE, Van Zee KJ, Hunt KK, Hahn OM, Carey LA, Partridge AH. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). J Clin Oncol. 2023 Jun 10;41(17):3184-3193. doi: 10.1200/JCO.22.02553. Epub 2023 Mar 28.
- Derived from this study: PubMed 34634438Cuttino LW, McCall L, Kubicky C, Ballman KV, Le-Petross H, Hunt KK, Haffty B, Rosenkranz KM, Boughey JC. The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Int J Radiat Oncol Biol Phys. 2022 Mar 1;112(3):636-642. doi: 10.1016/j.ijrobp.2021.09.054. Epub 2021 Oct 8.
- Derived from this study: PubMed 32699926Rosenkranz KM, Ballman K, McCall L, McCarthy C, Kubicky CD, Cuttino L, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC. Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study. Ann Surg Oncol. 2020 Nov;27(12):4650-4661. doi: 10.1245/s10434-020-08893-w. Epub 2020 Jul 22.
- Derived from this study: PubMed 29987605Rosenkranz KM, Ballman K, McCall L, Kubicky C, Cuttino L, Le-Petross H, Hunt KK, Giuliano A, Van Zee KJ, Haffty B, Boughey JC. The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Ann Surg Oncol. 2018 Oct;25(10):2858-2866. doi: 10.1245/s10434-018-6583-6. Epub 2018 Jul 9.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Judy Boughey, MD study chair
Mayo Clinic
350 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing therapeutic conventional surgery and whole breast irradiation in people with Breast Cancer, run by Alliance for Clinical Trials in Oncology at 350 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 350 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 30 Nov 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Local Recurrence (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01556243, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.